In 2018, Damon Runyon scientists made significant breakthroughs in cancer research that will lead to better prevention, diagnosis and treatments—to save lives.

**Damon Runyon Scientists**

- **Pioneered the development** of two new FDA-approved therapies for acute myeloid leukemia (AML), which have the revolutionary approach of reprogramming cancerous blood cells, instead of killing them.

- **Are conducting one of the first clinical trials** that will deliver a “one-two punch” against cancer using immunotherapy and a non-pathogenic virus that targets cancer cells.

- **Developed new liquid biopsies** (blood tests) that can quickly and accurately detect cancer and monitor treatment progress.

- **Engineered novel technology** to capture high-resolution, three-dimensional footage of cells in action, which will help scientists understand how cancer cells metastasize.

**Awards and Honors**

Four Damon Runyon alumni were elected to the National Academies of Sciences and Medicine (the science “Hall of Fame”): Roger J. Davis, PhD; Feng Zhang, PhD; Azad Bonni, MD, PhD; and Matthew L. Meyerson, MD, PhD.

Former Innovator Feng Zhang, PhD, received the Vilcek Prize for Creative Promise in Biomedical Science.

Former Grantee John Mendelsohn, MD, received the Tang Prize in Biopharmaceutical Science for pioneering the development of targeted drugs for colon and head/neck cancers.

Former Fellow Chuan He, PhD, was awarded the 2017 Paul Marks Prize for Cancer Research, which recognizes young investigators shaping the field.

Four Damon Runyon alumni were named prestigious Howard Hughes Medical Institute Investigators for exploring uncharted territories in biology.

Two former Damon Runyon scientists, Gordon J. Freeman, PhD, and Jedd D. Wolchok, MD, PhD, directly contributed to the immunotherapy checkpoint inhibitor development honored with the 2018 Nobel Prize in Physiology or Medicine.
DISCOVERING THE TALENT
TO DISCOVER THE CURE
www.damonrunyon.org
1.877.7CANCER

OUR MISSION
To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research.

RESEARCH PROGRAMS
• We are currently funding 209 researchers at 56 institutions across the nation.
• In fiscal year 2018, we awarded nearly $18.3 million in new grants to 69 exceptional scientists.

FINANCIAL INFORMATION

TOTAL REVENUE:
$22 MILLION

- Contributions 56.2%
- Damon Runyon Broadway Tickets 3.3%
- Donated Services 3.7%
- Bequests & Trusts 8.3%
- Misc. Income 1.0%
- Allocation from Investments 27.5%

TOTAL EXPENSES:
$22 MILLION

- Award Programs 83.5%
- Fundraising 14.0%
- General Administration 2.5%

100% of your donation funds brilliant scientists.
We pay our low overhead from Damon Runyon Broadway Tickets and our endowment. For more information, visit:
www.damonrunyon.org/broadway

DISCOVERING THE TALENT
TO DISCOVER THE CURE
www.damonrunyon.org
1.877.7CANCER

CHARITY NAVIGATOR
Four Star Charity